Taru Ilmarinen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Taru Ilmarinen has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Jaana Hagström
University of Turku and Turku University Hospital
4 shared publications - Leena-Maija Aaltonen
Department of Otorhinolaryngology – Head and Neck Surgery Helsinki University Hospital and University of Helsinki Helsinki Finland
4 shared publications - Ahmed Geneid
Department of Otorhinolaryngology and Phoniatrics-Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
3 shared publications Caj Haglund
Department of Surgery and Pathology, University of Helsinki and Helsinki University Hospital, P.O. Box 21, 00014 Helsinki, Finland; Research Programs Unit, Translational Cancer Biology, University of Helsinki, P.O. Box 21, 00014 Helsinki, Finland
3 shared publications- Eeva Auvinen
Department of Virology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
3 shared publications Leena-Maija Aaltonen
Department of Otorhinolaryngology - Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, P.O. Box 263, 00130 Helsinki, Finland
3 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Wiley in The Laryngoscope
Risk of Long‐Term Airway Sequelae and Mortality in Laryngeal Chondrosarcoma
Objective: In low‐ and intermediate‐grade laryngeal chondrosarcomas, nonradical surgery or even debulking is considered justifiable to preserve laryngeal function. However, tumor‐ and treatment‐related factors affecting the need for reoperation and long‐term risk for tracheostomy remain unclear. Methods: We retrospectively analyzed 20 patients with laryngeal chondrosarcoma, treated at the Helsinki University Hospital (Helsinki, Finland) between 2000 and 2023. Results: In total, four of 20 (20%) patients primarily underwent total laryngectomy. Sixteen of 20 (80%) patients primarily underwent either open partial laryngectomy or endoscopic debulking. In patients with cricoid cartilage tumors primarily treated with larynx‐preserving surgery, reoperation due to tumor recurrence or growth ( p = 0.003) and transformation from well or moderately differentiated to poorly differentiated or dedifferentiated histology ( p = 0.027) were significantly associated with permanent tracheostomy. Two patients presented with distant metastases and two died of laryngeal chondrosarcoma. Conclusion: Patients primarily presenting with low‐ or intermediate‐grade chondrosarcomas may develop higher‐grade local recurrence and distant metastases. Due to paradigm shift from radical to function‐preserving surgery in laryngeal chondrosarcoma, guidelines are needed for both primary tumor assessment and postoperative surveillance. To minimize the risk of long‐term dysfunction and mortality, early detection of unfavorable tumor histology or rapid growth requiring more aggressive treatment is mandatory. Level of Evidence: 4.
- 22 September 2026
- Published by Wiley in The Laryngoscope
Open AccessRisk of Long‐Term Airway Sequelae and Mortality in Laryngeal Chondrosarcoma
Objective: In low‐ and intermediate‐grade laryngeal chondrosarcomas, nonradical surgery or even debulking is considered justifiable to preserve laryngeal function. However, tumor‐ and treatment‐related factors affecting the need for reoperation and long‐term risk for tracheostomy remain unclear. Methods: We retrospectively analyzed 20 patients with laryngeal chondrosarcoma, treated at the Helsinki University Hospital (Helsinki, Finland) between 2000 and 2023. Results: In total, four of 20 (20%) patients primarily underwent total laryngectomy. Sixteen of 20 (80%) patients primarily underwent either open partial laryngectomy or endoscopic debulking. In patients with cricoid cartilage tumors primarily treated with larynx‐preserving surgery, reoperation due to tumor recurrence or growth ( p = 0.003) and transformation from well or moderately differentiated to poorly differentiated or dedifferentiated histology ( p = 0.027) were significantly associated with permanent tracheostomy. Two patients presented with distant metastases and two died of laryngeal chondrosarcoma. Conclusion: Patients primarily presenting with low‐ or intermediate‐grade chondrosarcomas may develop higher‐grade local recurrence and distant metastases. Due to paradigm shift from radical to function‐preserving surgery in laryngeal chondrosarcoma, guidelines are needed for both primary tumor assessment and postoperative surveillance. To minimize the risk of long‐term dysfunction and mortality, early detection of unfavorable tumor histology or rapid growth requiring more aggressive treatment is mandatory. Level of Evidence: 4.
- 7 August 2024
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 144 (5-6) , 404-408
Current aspects of the quality of head and neck cancer care – survey of the Scandinavian Society for Head and Neck Oncology
All Nordic countries have national cancer registries collecting data on head and neck cancer (HNC) incidence and survival. However, there is a lack of consensus on how other quality aspects should be monitored. We conducted a web-based survey to find opportunities for quality control and improvement. A web-based survey was sent to one otorhinolaryngology - head and neck (ORL-HN) surgeon, and one oncologist at each Nordic university hospital treating HNC. In total, 42 responses from all 21 university hospitals were included. In over half of the university hospitals, an oncologist, an ORL-HN surgeon, a pathologist, a radiologist, and a specialized nurse was always present at the multidisciplinary tumor board (MTB) meeting. Of 42 respondents 35 (83%) agreed that treatment delays were systematically recorded for each patient. Eleven of 21 (52%) oncologists agreed that side-effects of (chemo)radiotherapy were systematically recorded. Less than half of the respondents agreed that complications of surgery, and post-treatment quality of life (QOL) were systematically recorded. In the Nordic countries, the importance of HNC treatment timelines is well acknowledged. There is a lack of consensus on the composition of MTB meeting, and how treatment-related morbidity should be monitored outside clinical trials.
- 7 August 2024
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 144 (5-6) , 404-408
Current aspects of the quality of head and neck cancer care – survey of the Scandinavian Society for Head and Neck Oncology
All Nordic countries have national cancer registries collecting data on head and neck cancer (HNC) incidence and survival. However, there is a lack of consensus on how other quality aspects should be monitored. We conducted a web-based survey to find opportunities for quality control and improvement. A web-based survey was sent to one otorhinolaryngology - head and neck (ORL-HN) surgeon, and one oncologist at each Nordic university hospital treating HNC. In total, 42 responses from all 21 university hospitals were included. In over half of the university hospitals, an oncologist, an ORL-HN surgeon, a pathologist, a radiologist, and a specialized nurse was always present at the multidisciplinary tumor board (MTB) meeting. Of 42 respondents 35 (83%) agreed that treatment delays were systematically recorded for each patient. Eleven of 21 (52%) oncologists agreed that side-effects of (chemo)radiotherapy were systematically recorded. Less than half of the respondents agreed that complications of surgery, and post-treatment quality of life (QOL) were systematically recorded. In the Nordic countries, the importance of HNC treatment timelines is well acknowledged. There is a lack of consensus on the composition of MTB meeting, and how treatment-related morbidity should be monitored outside clinical trials.
- Open Access
- 11 February 2022
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 113 (1) , 96-100
Survival and Larynx Preservation in Early Glottic Cancer: A Randomized Trial Comparing Laser Surgery and Radiation Therapy
- 11 February 2022
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 113 (1) , 96-100
Open AccessSurvival and Larynx Preservation in Early Glottic Cancer: A Randomized Trial Comparing Laser Surgery and Radiation Therapy
- Open Access
- 13 September 2021
- Published by Springer Nature in Dysphagia
- Vol. 37 (4) , 995-1007
Finnish Version of the Eating Assessment Tool (F-EAT-10): A Valid and Reliable Patient-reported Outcome Measure for Dysphagia Evaluation
Our aim was to validate a Finnish version of the Eating Assessment Tool (F-EAT-10) for clinical use and to test its reliability and validity in a multicenter nationwide study. Normative data were acquired from 180 non-dysphagic participants (median age 57.0 years, 62.2% female). Dysphagia patients (n = 117, median age 69.7 years, 53.0% female) referred to fiberoptic endoscopic evaluation of swallowing (FEES) completed F-EAT-10 before the examination and after 2 weeks. Patients underwent the 100-ml water swallow test (WST) and FEES was evaluated using the following three scales: the Yale Pharyngeal Residue Severity Rating Scale, Penetration-Aspiration Scale, and the Dysphagia Outcome Severity Scale. An operative cohort of 19 patients (median age 75.8 years, 57.9% female) underwent an endoscopic operation on Zenker’s diverticulum, tight cricopharyngeal muscle diagnosed in videofluorography, or both. Patients completed the F-EAT-10 preoperatively and 3 months postoperatively. The cut-off score for controls was < 3 (sensitivity 94.0%, specificity 96.1%) suggesting that ≥ 3 is abnormal. Re-questionnaires for test–retest reliability analysis were available from 92 FEES patients and 123 controls. The intraclass correlation coefficient was excellent for the total F-EAT-10 score (0.93, 95% confidence interval 0.91–0.95). Pearson correlation coefficients were strong (p < 0.001) for each of the questions and the total score. Internal consistency as assessed by Cronbach’s alpha was excellent (0.95). Some correlations between findings in FEES and 100-ml WST with F-EAT-10 were observed. The change in subjective symptoms of operative patients paralleled the change in F-EAT-10. F-EAT-10 is a reliable, valid, and symptom-specific patient-reported outcome measure for assessing dysphagia among Finnish speakers.
- 13 September 2021
- Published by Springer Nature in Dysphagia
- Vol. 37 (4) , 995-1007
Open AccessFinnish Version of the Eating Assessment Tool (F-EAT-10): A Valid and Reliable Patient-reported Outcome Measure for Dysphagia Evaluation
Our aim was to validate a Finnish version of the Eating Assessment Tool (F-EAT-10) for clinical use and to test its reliability and validity in a multicenter nationwide study. Normative data were acquired from 180 non-dysphagic participants (median age 57.0 years, 62.2% female). Dysphagia patients (n = 117, median age 69.7 years, 53.0% female) referred to fiberoptic endoscopic evaluation of swallowing (FEES) completed F-EAT-10 before the examination and after 2 weeks. Patients underwent the 100-ml water swallow test (WST) and FEES was evaluated using the following three scales: the Yale Pharyngeal Residue Severity Rating Scale, Penetration-Aspiration Scale, and the Dysphagia Outcome Severity Scale. An operative cohort of 19 patients (median age 75.8 years, 57.9% female) underwent an endoscopic operation on Zenker’s diverticulum, tight cricopharyngeal muscle diagnosed in videofluorography, or both. Patients completed the F-EAT-10 preoperatively and 3 months postoperatively. The cut-off score for controls was < 3 (sensitivity 94.0%, specificity 96.1%) suggesting that ≥ 3 is abnormal. Re-questionnaires for test–retest reliability analysis were available from 92 FEES patients and 123 controls. The intraclass correlation coefficient was excellent for the total F-EAT-10 score (0.93, 95% confidence interval 0.91–0.95). Pearson correlation coefficients were strong (p < 0.001) for each of the questions and the total score. Internal consistency as assessed by Cronbach’s alpha was excellent (0.95). Some correlations between findings in FEES and 100-ml WST with F-EAT-10 were observed. The change in subjective symptoms of operative patients paralleled the change in F-EAT-10. F-EAT-10 is a reliable, valid, and symptom-specific patient-reported outcome measure for assessing dysphagia among Finnish speakers.
- 2 January 2021
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 278 (9) , 3489-3496
Enteral tube feeding of head and neck cancer patients undergoing definitive chemoradiotherapy in the Nordic Countries: Survey of the Scandinavian Society for Head and Neck Oncology
Purpose We assessed current policies and perceptions of enteral tube feeding in head and neck cancer (HNC) patients undergoing chemoradiotherapy (CRT). A web-based survey was used to compare the timing and method of tube feeding within and between the five Nordic countries, covering a population of 27 million. Methods From each of the 21 Nordic university hospitals, one oncologist and one otorhinolaryngology—head and neck (ORL-HN) surgeon responded to a survey. The respondents were asked whether tube insertion before the onset of CRT, or during CRT as required (prophylactic vs. reactive) was preferred. The use of a pretreatment nutritional screening tool and the choice of feeding route (nasogastric vs. gastrostomy tube) were assessed. In total, we analyzed responses from 21 oncologists and 21 ORL-HN surgeons. Results A tendency was observed towards decreasing the use of a PEG tube. Of the 21 university hospitals, only 2 (10%) reported using a prophylactic PEG tube in over half of HNC patients undergoing definitive CRT. The preferred method for reactive tube feeding was by a NG tube in 14 of 21 (67%), and by a PEG in 7 of 21 (33%). In general, both oncologists and ORL-HN surgeons were content with their current policy. Conclusions The practices for enteral tube feeding in HNC management vary within and between the Nordic countries. We suggest that unified protocols for tube feeding should be developed for this patient population.
- 2 January 2021
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 278 (9) , 3489-3496
Enteral tube feeding of head and neck cancer patients undergoing definitive chemoradiotherapy in the Nordic Countries: Survey of the Scandinavian Society for Head and Neck Oncology
Purpose We assessed current policies and perceptions of enteral tube feeding in head and neck cancer (HNC) patients undergoing chemoradiotherapy (CRT). A web-based survey was used to compare the timing and method of tube feeding within and between the five Nordic countries, covering a population of 27 million. Methods From each of the 21 Nordic university hospitals, one oncologist and one otorhinolaryngology—head and neck (ORL-HN) surgeon responded to a survey. The respondents were asked whether tube insertion before the onset of CRT, or during CRT as required (prophylactic vs. reactive) was preferred. The use of a pretreatment nutritional screening tool and the choice of feeding route (nasogastric vs. gastrostomy tube) were assessed. In total, we analyzed responses from 21 oncologists and 21 ORL-HN surgeons. Results A tendency was observed towards decreasing the use of a PEG tube. Of the 21 university hospitals, only 2 (10%) reported using a prophylactic PEG tube in over half of HNC patients undergoing definitive CRT. The preferred method for reactive tube feeding was by a NG tube in 14 of 21 (67%), and by a PEG in 7 of 21 (33%). In general, both oncologists and ORL-HN surgeons were content with their current policy. Conclusions The practices for enteral tube feeding in HNC management vary within and between the Nordic countries. We suggest that unified protocols for tube feeding should be developed for this patient population.
- 12 September 2019
- Published by Wiley in Head & Neck
- Vol. 42 (1) , 145-146
Reply to “Do not de‐escalate oncology care in oropharyngeal cancer routinely”
- 12 September 2019
- Published by Wiley in Head & Neck
- Vol. 42 (1) , 145-146
Reply to “Do not de‐escalate oncology care in oropharyngeal cancer routinely”
- 23 December 2018
- Published by Wiley in Head & Neck
- Vol. 41 (5) , 1457-1462
De‐escalation of post‐treatment surveillance in oropharyngeal cancer
Background: The majority of new oropharyngeal squamous cell carcinoma (OPSCC) cases are associated with human papillomavirus and favorable prognosis. Post‐treatment follow‐up should be targeted to patients at greatest risk for disease recurrence.Methods: To assess the benefits of routine clinical surveillance in OPSCC, we reviewed all follow‐up visits conducted in 2014 at Helsinki University Hospital Department of Otorhinolaryngology.Results: Of 366 visits, 26 (7%) were from patients presenting with a new symptom, and disease recurrence was detected in four. The presence of a new symptom was significantly associated with disease recurrence (P < 0.001). Of 366 visits, 340 (93%) were from patients presenting without new symptoms, and not a single recurrence was found during these visits.Conclusions: Based on our findings, and previous studies assessing the prognosis and pattern of recurrent OPSCC, we concluded that the number of routine post‐treatment visits can be reduced. Follow‐up should rather focus on symptom‐directed examinations.
- 23 December 2018
- Published by Wiley in Head & Neck
- Vol. 41 (5) , 1457-1462
De‐escalation of post‐treatment surveillance in oropharyngeal cancer
Background: The majority of new oropharyngeal squamous cell carcinoma (OPSCC) cases are associated with human papillomavirus and favorable prognosis. Post‐treatment follow‐up should be targeted to patients at greatest risk for disease recurrence.Methods: To assess the benefits of routine clinical surveillance in OPSCC, we reviewed all follow‐up visits conducted in 2014 at Helsinki University Hospital Department of Otorhinolaryngology.Results: Of 366 visits, 26 (7%) were from patients presenting with a new symptom, and disease recurrence was detected in four. The presence of a new symptom was significantly associated with disease recurrence (P < 0.001). Of 366 visits, 340 (93%) were from patients presenting without new symptoms, and not a single recurrence was found during these visits.Conclusions: Based on our findings, and previous studies assessing the prognosis and pattern of recurrent OPSCC, we concluded that the number of routine post‐treatment visits can be reduced. Follow‐up should rather focus on symptom‐directed examinations.
- 14 December 2018
- Published by Wiley in Head & Neck
- Vol. 41 (2) , 309-314
Serum matrix metalloproteinase 8 and tissue inhibitor of metalloproteinase 1: Potential markers for malignant transformation of recurrent respiratory papillomatosis and for prognosis of laryngeal cancer
Background: Biomarkers that could predict malignant transformation of recurrent respiratory papillomatosis (RRP) would be useful in patient follow‐up. We investigated whether serum matrix metalloproteinase 8 (MMP‐8) and tissue inhibitor of metalloproteinase 1 (TIMP‐1) could predict malignant transformation of RRP and whether they associate with survival in laryngeal squamous cell carcinoma (LSCC) without preexisting RRP.Methods: We analyzed serum MMP‐8 (S‐MMP‐8) and serum TIMP‐1 (s‐TIMP‐1) in 114 patients: 55 were treated for RRP and 59 for LSCC without preexisting RRP. Five patients with RRP developed LSCC during follow‐up.Results: Elevated S‐MMP‐8 level in RRP was associated with malignant transformation (P = .01). Compared to patients with RRP, S‐MMP‐8 in patients with LSCC was significantly higher (P < .001). Increased S‐TIMP‐1 level in LSCC was associated with poor overall survival (P = .02) and recurrence‐free survival (P = .05).Conclusion: In RRP, high S‐MMP‐8 may predict malignant transformation. In LSCC, elevated S‐TIMP‐1 is connected to poor survival.
- 14 December 2018
- Published by Wiley in Head & Neck
- Vol. 41 (2) , 309-314
Serum matrix metalloproteinase 8 and tissue inhibitor of metalloproteinase 1: Potential markers for malignant transformation of recurrent respiratory papillomatosis and for prognosis of laryngeal cancer
Background: Biomarkers that could predict malignant transformation of recurrent respiratory papillomatosis (RRP) would be useful in patient follow‐up. We investigated whether serum matrix metalloproteinase 8 (MMP‐8) and tissue inhibitor of metalloproteinase 1 (TIMP‐1) could predict malignant transformation of RRP and whether they associate with survival in laryngeal squamous cell carcinoma (LSCC) without preexisting RRP.Methods: We analyzed serum MMP‐8 (S‐MMP‐8) and serum TIMP‐1 (s‐TIMP‐1) in 114 patients: 55 were treated for RRP and 59 for LSCC without preexisting RRP. Five patients with RRP developed LSCC during follow‐up.Results: Elevated S‐MMP‐8 level in RRP was associated with malignant transformation (P = .01). Compared to patients with RRP, S‐MMP‐8 in patients with LSCC was significantly higher (P < .001). Increased S‐TIMP‐1 level in LSCC was associated with poor overall survival (P = .02) and recurrence‐free survival (P = .05).Conclusion: In RRP, high S‐MMP‐8 may predict malignant transformation. In LSCC, elevated S‐TIMP‐1 is connected to poor survival.
- 1 October 2017
- Published by Elsevier in Oral Oncology
- Vol. 73, 77-82
Prevalence of high-risk human papillomavirus infection and cancer gene mutations in nonmalignant tonsils
- 1 October 2017
- Published by Elsevier in Oral Oncology
- Vol. 73, 77-82
Prevalence of high-risk human papillomavirus infection and cancer gene mutations in nonmalignant tonsils
- 2 November 2016
- Published by Taylor & Francis in Infectious Diseases
- Vol. 49 (4) , 302-307
Systemic matrix metalloproteinase-8 response in chronic tonsillitis
The development of several life-long diseases, such as coronary heart disease, is affected by low-grade systemic inflammation. Data on the potential long-term health effects of chronic tonsillitis are limited. Many inflammatory conditions present with enhanced systemic matrix metalloproteinase (MMP)-8 response. In head and neck cancer, high plasma level of tissue inhibitor of metalloproteinase (TIMP)-1 predicts poor prognosis. We analyzed S-MMP-8 with immunofluorometric assay and S-TIMP-1 with an immunosorbent assay in 175 consecutive patients undergoing tonsillectomy for benign tonsillar disease, and in 33 control patients with tonsillar squamous cell carcinoma. Tonsillar human papillomavirus (HPV) status was determined by PCR. In patients with benign tonsillar disease, chronic tonsillitis without hypertrophy was associated with enhanced systemic MMP-8 response. Compared to patients with benign tonsillar disease, patients with tonsillar squamous cell carcinoma had significantly higher concentrations of S-MMP-8 and S-TIMP-1. Neither S-MMP-8 nor S-TIMP-1 correlated with tonsillar HPV positivity.
- 2 November 2016
- Published by Taylor & Francis in Infectious Diseases
- Vol. 49 (4) , 302-307
Systemic matrix metalloproteinase-8 response in chronic tonsillitis
The development of several life-long diseases, such as coronary heart disease, is affected by low-grade systemic inflammation. Data on the potential long-term health effects of chronic tonsillitis are limited. Many inflammatory conditions present with enhanced systemic matrix metalloproteinase (MMP)-8 response. In head and neck cancer, high plasma level of tissue inhibitor of metalloproteinase (TIMP)-1 predicts poor prognosis. We analyzed S-MMP-8 with immunofluorometric assay and S-TIMP-1 with an immunosorbent assay in 175 consecutive patients undergoing tonsillectomy for benign tonsillar disease, and in 33 control patients with tonsillar squamous cell carcinoma. Tonsillar human papillomavirus (HPV) status was determined by PCR. In patients with benign tonsillar disease, chronic tonsillitis without hypertrophy was associated with enhanced systemic MMP-8 response. Compared to patients with benign tonsillar disease, patients with tonsillar squamous cell carcinoma had significantly higher concentrations of S-MMP-8 and S-TIMP-1. Neither S-MMP-8 nor S-TIMP-1 correlated with tonsillar HPV positivity.